iShares Self-Driving EV and Tech ETF (ARCA: IDRV)

에 대한 최신 뉴스 iShares Self-Driving EV and Tech ETF (ARCA:IDRV)

Consumer Cyclical

Industrials

Basic Materials

Other

Technology

Financial Services

The index is composed of equity securities of companies listed in one of 43 developed or emerging market countries that derive a certain specified percentage of their revenue from selected autonomous or electric vehicle-related industries, as defined by IDI. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index. It is non-diversified.

Rivian Automotive

Tesla, Inc.

Lucid Group Inc

Denso Corp

Byd Co Ltd H

Xpeng Inc-A Shrs

Abb Ltd

Schneider Electric Se

Lg Energy Solution

iShares Self-Driving EV and Tech ETF

Government

Regulations

Sector ETFs

Global

ETFs

DRIV

FTXR

IDRV

STLA

도널드 트럼프 대통령은 멕시코에서 수입하는 제품에 25% 관세를 부과할 계획을 실행에 옮겼다. 이 관세는 캐나다(25%)와 중국(10%)에 대한 관세와 함께 토요일에 발효된다. 이 조치는 멕시코 자동차 부품에 크게 의존하는 회사들에 영향을 미칠 것으로 예상된다.

미국 자동차 ETF 3종목, 트럼프의 멕시코 수입품에 25% 관세 발표로 비상 상황에 직면

ARKK

KARS

LCID

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

RIVN

TSLA

XPEV

도널드 트럼프 대통령은 2030년까지 전기차(EV) 보급률 50%를 목표로 한 조 바이든 전 대통령의 행정명령을 취소했다. 이 결정은 자동차 업계 전반에 파장을 일으켰다.

트럼프의 전기차 정책 변경, 관련 ETF 중 승자와 패자는?

Markets

HAIL

테슬라(NASDAQ:TSLA)의 미국 전기차(EV) 시장 점유율이 처음으로 절반 아래로 떨어졌다. 어떤 일이 (What Happened): 일론 머스크(Elon Musk)가 이끄는 이 회사는 한 때 지배했던 부문에서 더 많은 자동차 경쟁사들이 시장 점유율을 차지하는 것을 보고 있다.

테슬라, 미국 국내 분기별 전기차 시장 점유율 처음으로 50% 미만으로 하락

Scotiabank analyst Patrick Colville maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Sector Perform and lowers the price target from $275 to $240.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on MongoDB, Lowers Price Target to $240

Walgreens Boots Alliance Agrees To Be Acquired By Sycamore Partners; Total Value Of Transaction Represents Up To $23.7B

Scotiabank analyst Nicholas Yulico maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Sector Perform and lowers the price target from $22 to $21.

Scotiabank Maintains Sector Perform on Macerich, Lowers Price Target to $21

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 14.63% on an annualized basis producing an average annual return of 25.48%. Currently, Veeva Systems has a market capitalization of $37.83 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $9,733.72 today based on a price of $233.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741299310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VEEV

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Amid an especially volatile <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">start to 2025</a>, small-cap stocks have struggled. Are they now a buy at depressed valuations?
Russell 2000: The Russell 2000, as reflected by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), has dropped nearly 15% since December 2024. This constitutes a market correction.
The Trump Administration has embraced domestic and foreign policies that Former Treasury Secretary&nbsp;Larry Summers&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43649860/larry-summers-and-peter-schiff-warn-of-rising-inflation-risks-as-markets-slash-fed-rate-cut-expectations-most-sensitive-moment">labels as inflationary</a>. Higher prices could lead to higher interest rates, which disproportionately affect smaller companies with floating-rate debt.
The Russell index <a href="https://research.ftserussell.com/Analytics/FactSheets/Home/DownloadSingleIssue?issueName=US2000USD&amp;isManual=True">contains</a> 2,000 companies with an average market cap of around $1 billion. Higher-weighted components are likely to have outperformed the rest of the index and are not necessarily representative of the entire Russell 2000. Still, they provide a glimpse into how investors are valuing small-cap companies.
Here&#8217;s how the top stocks in the IWM have performed since the ETF&#8217;s correction began in December 2024:
Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)
<ul>
<li>Dec. 2, 2024, Price: $150.92​</li>
<li>March 6, 2025, Price: $138.11​</li>
<li>Percentage Change: -8.49%</li>
</ul>
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>)
<ul>
<li>Dec. 2, 2024, Price: $72.42​</li>
<li>March 6, 2025, Price: $75.02​</li>
<li>Percentage Change: +3.59%​</li>
</ul>
Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)
<ul>
<li>Dec. 2, 2024, Price: $91.60​</li>
<li>March 6, 2025, Price: $74.81</li>
<li>Percentage Change: -18.33%​</li>
</ul>
SouthState Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NASDAQ">SSB</a>)
<ul>
<li>Dec. 2, 2024, Price: $109.35</li>
<li>March 6, 2025, Price: $92.37</li>
<li>Percentage Change: -15.53%​</li>
</ul>
FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>)
<ul>
<li>Dec. 2, 2024, Price: $166.8​</li>
<li>March 6, 2025, Price: $108.2​8</li>
<li>Percentage Change: -35.08%​</li>
</ul>
Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)
<ul>
<li>Dec. 2, 2024, Price: $24.16</li>
<li>March 6, 2025, Price: $18.66</li>
<li>Percentage Change: -22.76%​</li>
</ul>
Applied Industrial Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>)
<ul>
<li>Dec. 2, 2024, Price: $272.91</li>
<li>March 6, 2025, Price: $229.00</li>
<li>Percentage Change: -16.09%​</li>
</ul>
Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>)
<ul>
<li>Dec. 2, 2024, Price: $47.80​</li>
<li>March 6, 2025, Price: $42.07</li>
<li>Percentage Change: -11.99%​</li>
</ul>
Ufp Industries Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFPI#NASDAQ">UFPI</a>) and&nbsp;Fluor Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) are also among the ETF&#8217;s top holdings.
Benzinga Edge evaluates stocks on a valuation, momentum and growth basis.
UFP, a holding company based in Grand Rapids, Michigan, performs well under the value criterion, scoring 78.64 out of 100. However, the stock does not have momentum, scoring 32.82. It is also not the fastest-growing company, grading 33.35. The stock is down 20.5% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/UFPI"><img loading="lazy" decoding="async" width="1024" height="229" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png" alt="" class="wp-image-812940" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-1024x229.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-300x67.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM-768x172.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150724/Screenshot-2025-03-06-at-3.07.19-PM.png 1314w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Fluor, an engineering and construction firm, rates high according to its intrinsic value, scoring at 93.6. Still, recent price action indicates its growth and momentum prospects are not high, scoring 15.32 and 29.26, respectively. The stock is down 33.6% since Dec. 2, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/FLR"><img loading="lazy" decoding="async" width="1024" height="232" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png" alt="" class="wp-image-812935" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-1024x232.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-300x68.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM-768x174.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06150443/Screenshot-2025-03-06-at-3.04.39-PM.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li>Unlock the rest of the BZ Edge Rankings and see how <a href="https://www.benzinga.com/quote/fn">another small-cap stock stacks up</a>.</li>
</ul>
S&amp;P 500 Comparison: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks 500 of the largest U.S. companies, has fared slightly better than the Russell 2000. The index is down around 2% since Dec. 2, 2024.
On an earnings basis, investors are trading the S&amp;P 500 at a much higher multiple than the Russell 2000. The S&amp;P as a whole is trading 21.63 times above earnings compared to the small-cap index&#8217;s 14.84 times. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44174230/short-seller-targets-gorilla-technology-group-stock-investors-take-profits">Short Seller Targets Gorilla Technology Group Stock, Investors Take Profits</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Broad U.S. Equity ETFs

CRDO

FTAI

INSM

PCVX

RKLB

UFPI

Are Small-Cap Stocks A Buy After Russell 2000 Correction?

Trading Halt: Halted at 5:14:09 p.m. ET - Trading Halt: Halt News Pending

Scotiabank analyst Brandon Bingham maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Sector Outperform and raises the price target from $247 to $254.

Scotiabank Maintains Sector Outperform on Cheniere Energy, Raises Price Target to $254

Scotiabank analyst Brandon Bingham maintains Kinetik Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNTK#NYSE">KNTK</a>) with a Sector Outperform and lowers the price target from $62 to $60.

KNTK

Scotiabank Maintains Sector Outperform on Kinetik Holdings, Lowers Price Target to $60

Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) released its fourth-quarter results after Thursday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/03/b44179559/samsara-reports-fourth-quarter-and-full-fiscal-year-2025-financial-results">from the quarter.</a>
The Details:&nbsp;Samsara reported quarterly earnings of&nbsp;11 cents&nbsp;per share, which beat the analyst consensus estimate of&nbsp;seven cents. Quarterly revenues of $346.3 million beat the analyst consensus estimate of&nbsp;$335.37 million&nbsp;and grew from $276.274 million&nbsp;in the same period last year.
The company also reported ending ARR of $1.458 billion, representing 33% year-over-year adjusted growth, and 2,506 customers with ARR over $100,000, representing 36% year-over-year growth. 
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/03/44172028/trade-turmoil-oil-slides-whats-driving-markets-thursday">Trade Turmoil, Oil Slides: What&#8217;s Driving Markets Thursday?</a>&nbsp;
&#8220;Fiscal year 2025 was another year of durable and efficient growth. We ended the year with close to $1.5 billion of ARR, achieving 33% year-over-year adjusted growth,&#8221; said Sanjit Biswas, CEO of Samsara. &#8220;We&#8217;re operating at a rare combination of growth, scale and profitability, and we see a large market opportunity ahead of us.&#8221;
Outlook: Samsara sees first-quarter EPS between five cents and six cents, versus the five cents estimate, and revenue in a range of $350 million to $352 million, versus the $351.35 million estimate.
IOT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Samsara shares were down 3.53% after-hours at $40.40 Thursday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a></li>
</ul>
Image: Courtesy of Samsara, Inc.

Earnings

After-Hours Center

Movers

Tech

Samsara Shares Drop Despite Better-Than-Expected Q4 Results

Consolidated copper production for 2025 is expected to range between 75,000 to 85,000 tonnes. The Company remains focused on steadily increasing plant throughput and achieving commercial production at the Tucumã Operation in H1 2025.&nbsp;
As a result, copper production is expected to increase sequentially each quarter, with Tucumã expected to contribute significantly to the full-year consolidated copper production.

Guidance

Ero Copper Expects 2025 Capital Expenditures To Decrease To Range Of $230M - $270M

Scotiabank analyst Phil Hardie maintains First National Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FN#TSX">FN</a>) with a Sector Perform and raises the price target from C$44 to C$45.

TSX:FN

Scotiabank Maintains Sector Perform on First National Financial, Raises Price Target to C$45

Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.31 by 45.16 percent. This is a 19.05 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $122.50 million which missed the analyst consensus estimate of $146.57 million by 16.42 percent. This is a 5.24 percent increase over sales of $116.40 million the same period last year.

Earnings Misses

Ero Copper Q4 2024 Adj EPS $0.17 Misses $0.31 Estimate, Sales $122.50M Miss $146.57M Estimate

Scotiabank analyst Holly Stewart maintains Enterprise Prods Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) with a Sector Perform and raises the price target from $33 to $35.

Scotiabank Maintains Sector Perform on Enterprise Prods Partners, Raises Price Target to $35

The maximum number of common shares which may be purchased by Sprott during the NCIB will not exceed 645,333 common shares being approximately 2.5% of 25.81 million (representing the number of issued and outstanding common shares as of February 28, 2025).

Buybacks

Sprott Says TSX Approved Notice Of Intention To Make Normal Course Issuer Bid; Plan Not To Exceed 645,333 Common Shares

A federal judge extended an order on Thursday that prevents <a href="https://www.benzinga.com/topic/donald-trump">the Trump administration</a> from freezing billions in congressionally approved funds to 22 states and the District of Columbia.
The New York Times <a href="https://www.nytimes.com/2025/03/06/us/politics/trump-funding-freeze-states.html">reported</a> that the judge found the administration had overstepped in trying to stop the agencies from using money appropriated by Congress.
Judge John J. McConnell Jr. of the Federal District Court for the District of Rhode Island, said in the opinion that the case amounted to executive overreach.
"Here, the executive put itself above Congress," McConnell wrote. "It imposed a categorical mandate on the spending of congressionally appropriated and obligated funds without regard to Congress's authority to control spending."
What Happened: Thursday&#8217;s injunction, the second ordered by a federal court blocking the spending freeze, marks a victory for Democratic attorneys general who filed suit against the Trump administration over its efforts to slash trillions of dollars in order to evaluate whether the programs in question aligned with the president&#8217;s policy goals.
The White House budget office memo that got the ball rolling last month sent millions of workers across the country into a collective state of confusion and insecurity, after which a coalition of state attorneys general launched lawsuits.
The Judge McConnell&#8217;s order, aimed at all the federal agencies cited in the White House memo, directs them to refrain from "pausing, freezing, blocking, canceling, suspending, terminating or otherwise impeding the disbursement of appropriated federal funds to the States under awarded grants, executed contracts or other executed financial obligations."
While the decision represents a rebuke of the spending freeze, <a href="https://www.npr.org/2025/03/06/nx-s1-5312069/trump-federal-funding-freeze-court-order">noted</a> NPR, the preliminary injunction only applies in the states that brought the challenge.
Nevertheless, the ruling was praised by the attorneys general who filed the lawsuit.
&#8220;Americans should feel encouraged that the President cannot impose his will where he does not have the constitutional power to do so. And while he may continue to try, we will continue to fight,&#8221; Rhode Island&#8217;s Attorney General Peter Neronha said&nbsp;<a href="https://riag.ri.gov/press-releases/attorney-general-neronha-recommits-defending-constitution-following-court-decision" target="_blank" rel="noreferrer noopener">in a statement</a>.
"We don't have kings in this country, and today's preliminary injunction reaffirms that&#8221; he continued. "The President's federal funding freeze would be laughable if it wasn't so utterly destructive. It flies in the face of everything we know to be true about our government, namely our separation of powers, by attempting to render the Congress as irrelevant."
<h2 class="wp-block-heading">Trump-Musk Response?</h2>
​As of now, neither President Donald Trump nor Elon Musk, head of the Department of Government Efficiency (DOGE), has issued an official response to the recent decision. However, Musk <a href="https://x.com/elonmusk/status/1897671125775138945">commented </a>on X (formerly Twitter), stating, &#8220;The Democratic government-funded NGO scam might be the biggest theft of taxpayer money ever.&#8221; ​
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Federal Judge Blocks Trump's Freeze On Billions In Congressional Funds: 'Executive Put Itself Above Congress'

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/03/n44179784/broadcom-inc-announces-first-quarter-fiscal-year-2025-financial-results-and-quarterly-dividend">from the quarter</a>.
Q1 Earnings: Broadcom reported first-quarter revenue of $14.92 billion, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $14.61 billion, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The semiconductor company reported first-quarter adjusted earnings of $1.60 per share, beating analyst estimates of $1.49 per share.
Total revenue was up 25% on a year-over-year basis, driven by strength in AI semiconductor solutions and infrastructure software. Broadcom generated $6.11 billion in cash from operations and $6.01 billion in free cash flow during the quarter. The company ended the quarter with approximately $9.31 billion in cash and cash equivalents.
&#8220;Q1&nbsp;AI revenue grew&nbsp;77%&nbsp;year-over-year to&nbsp;$4.1 billion&nbsp;and infrastructure software revenue grew&nbsp;47%&nbsp;year-over-year to&nbsp;$6.7 billion,&#8221; said&nbsp;Hock Tan, president and CEO of Broadcom.
&#8220;We expect continued strength in AI semiconductor revenue of&nbsp;$4.4 billion&nbsp;in&nbsp;Q2, as hyperscale partners continue to invest in AI XPUs and connectivity solutions for AI data centers.&#8221;
Broadcom&#8217;s board approved a quarterly cash dividend of 59 cents per share, payable on March 31 to shareholders of record as of March 20.
See Also: <a href="https://www.benzinga.com/news/global/25/03/44176918/trump-delays-mexico-tariffs-for-a-month-economic-uncertainty-persits">Trump Delays Mexico Tariffs For A Month, Economic Uncertainty Persists</a>
Outlook: Broadcom expects second-quarter revenue of approximately $14.9 billion, versus estimates of $14.76 billion. The company anticipates first-quarter adjusted EBITDA of approximately 66% of projected revenue.
Broadcom executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
AVGO Price Action: <a href="https://www.benzinga.com/quote/AVGO" target="_blank" rel="noreferrer noopener">Broadcom shares</a> were up 8.73% after hours, trading at $195.11 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

AVGO

Broadcom Stock Surges On Q1 Earnings Beat, Revenue Beat, Strong Guidance: 'We Expect Continued Strength In AI Semiconductor Revenue'

BRBR

BellRing Brands Board Approves $300M Share Repurchase Authorization Over Next Two Years

Throughout the last three months, 4 analysts have evaluated EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $30.25, with a high estimate of $33.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 3.14% increase from the previous average price target of $29.33.
<img src="https://www.benzinga.com/files/images/story/2025/1741298458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of EyePoint Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Daniil Gataulin</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$33.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to EyePoint Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EyePoint Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into EyePoint Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EYPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EyePoint Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into EyePoint Pharmaceuticals's Background</h2>
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
<h3>EyePoint Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, EyePoint Pharmaceuticals faced challenges, resulting in a decline of approximately -30.77% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: EyePoint Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -278.99%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): EyePoint Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of -13.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): EyePoint Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.39%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, EyePoint Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EYPT

Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews

Discover Financial servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.52%. Currently, Discover Financial servs has a market capitalization of $43.44 billion. 
Buying $100 In DFS: If an investor had bought $100 of DFS stock 5 years ago, it would be worth $315.32 today based on a price of $172.67 for DFS at the time of writing.
<h3>Discover Financial servs's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741298419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Discover Financial servs 5 Years Ago Would Be Worth Today

Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) sees Q1 sales of $33.000 million-$35.000 million vs $35.38 million analyst estimate.

ASUR

Asure Software Sees Q1 Sales $33.000M-$35.000M vs $35.38M Est

도널드 트럼프 대통령은 멕시코에서 수입하는 제품에 25% 관세를 부과할 계획을 실행에 옮겼다. 이 관세는 캐나다(25%)와 중국(10%)에 대한 관세와 함께 토요일에 발효된다. 이 조치는 멕시코 자동차 부품에 크게 의존하는 회사들에 영향을 미칠 것으로 예상된다.
자동차 제조사인 제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)는 로이터 보도에 따르면 멕시코 공장에서 생산한 차량을 북미로 수출하고 있다. 이 보도에서는 포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)와 스텔란티스 NV(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)와 같은 다른 미국 자동차 제조사들도 타격을 받을 가능성이 높다고 언급했다. 이들 회사는 멕시코에서 생산하는 주요 미국 제조업체들이다.
자동차 부문에 집중된 <a href="https://www.benzinga.com/etfs">ETF</a>들도 상당한 도전에 직면해 있다. 현재 주목받고 있는 세 가지 ETF는 다음과 같다:
First Trust Nasdaq Transportation ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>): 이 ETF는 주요 자동차 제조사와 자동차 부품 공급사를 포함한 운송 회사에 대한 노출을 제공한다. 제너럴 모터스와 포드와 같은 회사들이 포트폴리오에 포함되어 있다. <a href="https://www.statista.com/statistics/898955/mexico-motor-vehicle-production-brand/#:~:text=In%202024%2C%20the%20number%20of,the%20American%20company%20General%20Motors.">스태티스타(Statista)</a>의 최근 보고서에 따르면, 2024년에는 &#8220;멕시코에서 생산된 경량 차량의 수가 거의 400만 대에 달하며, 그 중 약 22.3%가 미국 회사인 제너럴 모터스에서 생산한 것이다.&#8221;
테슬라와 같이 멕시코 누에보 레온에 새로운 공장을 발표한 회사들도 이 ETF의 보유 종목이다.
Global X Autonomous &amp; Electric Vehicles ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>): 이 펀드는 전기차와 자율주행차 관련 회사들에 투자한다. 포드는 이 ETF의 주요 보유 종목 중 하나이다.
iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>): 이 ETF는 전기차와 자율주행 기술에 종사하는 회사들을 겨냥하고 있다. 폭스바겐과 같이 멕시코에서 운영되는 자동차 제조사와 부품 공급사들도 포함되며, 이들이 제안된 관세의 영향을 받을 수 있음을 나타낸다. 주목할 점은, 폭스바겐이 2024년 1월부터 7월까지 멕시코에서 북미로 109,735대의 경량 차량을 수출했다는 것이다. 이는 멕시코 자동차 제조사 협회에 의해 보고되었다.
또한 읽기: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps">연준의 선호 인플레이션 지표가 예상대로 상승하고 소비자 지출이 9개월 만에 가장 빠른 속도로 증가</a>
<h1 class="wp-block-heading">제안된 관세의 영향</h1>
작년 11월, 번스타인의 애널리스트 다니엘 로에스카(Daniel Roeska)는 노트에서 폭스바겐, 스텔란티스, 제너럴 모터스 및 포드가 가장 큰 타격을 받을 것이라고 언급했다. &#8220;멕시코와 캐나다에 대한 25% 관세는 미국 자동차 산업을 심각하게 마비시킬 것&#8221;이라고 말했다.
AP 통신의 이전 보도에 따르면, 제너럴 모터스는 미국에서 판매하는 차량의 약 30%를 캐나다와 멕시코에서 수입하고 있다. 인기 있는 픽업 트럭의 약 55%도 멕시코와 캐나다에서 수입된다. 제너럴 모터스와 다른 자동차 제조사들의 이익이 영향을 받을 것으로 예상된다.
국제무역청에 따르면, 멕시코는 세계에서 7번째로 큰 승용차 <a href="https://www.trade.gov/country-commercial-guides/mexico-automotive-industry#:~:text=Leading%20Sub%2DSectors%20and%20Opportunities,Tech%20Top%20Export%20Market%20Ranking.">제조국</a>으로 연간 350만 대의 차량을 생산하고 있다. 멕시코에서 생산된 차량의 88%는 수출되며, 이 중 76%는 미국으로 수출된다.
<h1 class="wp-block-heading">북미 자동차 공급망의 깊은 통합</h1>
수십 년간의 자유무역은 미국, 캐나다 및 멕시코의 자동차 산업을 깊이 통합하였다. <a href="https://www.cato.org/blog/seven-charts-show-how-us-tariffs-would-harm-american-auto-industry#:~:text=Mexico%20and%20Canada%20Are%20the,%2C%22%20US%20International%20Trade%20Commission.">케이토 연구소</a>(Cato Institute)의 연구에 따르면, 멕시코와 캐나다는 미국 자동차 및 부품 수입 및 수출의 거의 절반을 차지한다.
이는 관세 인상이 단순히 미국 소비자와 제조사의 비용을 증가시킬 뿐만 아니라, 멕시코와 캐나다의 보복 조치를 촉발하여 미국 자동차 수출을 감소시킬 수 있다는 것을 의미한다.
또한, 멕시코에서 조립된 차량은 종종 높은 비율의 미국산 부품이 포함되어 있다. 2019년 연구에 따르면, 멕시코에서 수입된 자동차의 외국 가치 추가분의 거의 74%가 미국에서 발생한 것이다. 또 다른 피터슨 국제 경제 연구소의 분석에 따르면, 멕시코에서 수입된 차량의 총 가치 추가분의 38%가 미국산이다. 멕시코가 보복 조치를 취할 경우, 이는 미국에도 나쁜 소식이 될 수 있다.
간단히 말해, &#8220;멕시코에서 제조된&#8221; 차량에 25% 관세를 부과하는 것은 미국의 이 차량을 공급하는 노동자와 사업체에도 의도치 않은 피해를 줄 수 있다.
이미 얽혀 있는 공급망의 혼란으로 인한 위험은 상당히 높다. 이러한 ETF에 투자한 투자자들은 개발 동향을 면밀히 주시하고, 관세가 기초 회사들의 수익성에 큰 영향을 미칠 수 있음을 명심해야 한다.

다음 읽기: 
<ul>
<li><a href="http://benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">트럼프의 25% 관세가 캐나다와 멕시코 경제를 파탄낼 수 있으며, 미국 자동차 산업에 타격을 줄 것이라고 분석가들이 경고</a></li>
</ul>
사진: Ford Motor Co. 제공
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

도널드 트럼프 대통령은 2030년까지 전기차(EV) 보급률 50%를 목표로 한 조 바이든 전 대통령의 행정명령을 취소했다. 이 결정은 자동차 업계 전반에 파장을 일으켰다.
전기차 보조금 폐지 가능성, 주정부 차원의 배출권 면제 제한, 연방 배출권 규제 완화로 전기차(EV) 및 자동차 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">섹터에 노출된 ETF는</a> 좋은 쪽으로든 나쁜 쪽으로든 지각변동을 맞이할 것이다.
<h3>전기차 중심 ETF: 승자와 패자</h3>
Global X Autonomous &amp; Electric Vehicles ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>), iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>) 등 <a href="//www.benzinga.com/electric-vehicles"" target="_blank" rel="noopener">미국 기반 전기차 제조업체에 크게 의존</a>하는 ETF는 해당 기업 주식에 직접적으로 노출되어 있어 잠재적인 역풍을 맞고 있다. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), 리비안(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), 루시드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) 같은 기업은 연방 세액공제가 폐지되면 소비자 수요가 감소할 수 있다.
그러나 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), 샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), 리오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) 같은 중국 자동차 제조업체를 상당수 보유하고 있는 KraneShares Electric Vehicles 및 Future Mobility ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KARS#NYSE">KARS</a>)처럼 글로벌 자동차 섹터 중심의 EV ETF는 회복력을 보일 수 있다. <a href="https://www.benzinga.com/markets/25/01/43091254/teslas-chinese-rivals-li-xpeng-nio-surge-while-rivian-declines-in-pre-market-as-trump-revokes-bidens-ev-target" target="_blank" rel="noopener">중국 전기차 스타트업</a>은 트럼프의 발표 이후 내수 판매 호조와 중국을 겨냥한 새로운 관세 부재에 힘입어 랠리를 펼쳤다.
<h3>테슬라의 독보적인 위치</h3>
여기서 한 가지 흥미로운 점을 생각해 볼 필요가 있다. 대부분의 전기차 중심 ETF의 주요 구성 종목인 테슬라는 정책 변경에도 불구하고 1월 22일 기준으로 1.08% 상승했다. 트럼프의 대선 캠페인에 자금을 지원한 일론 머스크 CEO는 전기차 보조금 중단에 동의했다.
머스크는 세액공제 폐지가<a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably" target="_blank" rel="noopener"> 테슬라에는 약간의 영향만 미치겠지만</a> 보조금에 의존하는 경쟁사에게는 큰 충격이 될 수 있다고 말했다. 즉, 테슬라가 잠재적 수혜자가 될 수도 있고 불리한 입장에 처할 수도 있다. 테슬라 비중이 큰 ETF로는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), First Trust NASDAQ Clean Edge Green Energy Index Fund(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>) 등이 있다.
<h3>소비자 행동과 장기적인 논의</h3>
7,500달러의 연방 전기차 세액공제 혜택이 폐지될 경우, 특히 럭셔리 부문에서 소비자의 관심이 가솔린 차량으로 다시 옮겨갈 수 있다. 테슬라의 연구원 트로이 테슬라이크는 세액공제가 폐지되면 테슬라가 가솔린 럭셔리 브랜드에 시장 점유율을 잃을 수 있다고 <a href="https://www.benzinga.com/24/12/42641207/researcher-says-cancelation-of-7500-ev-tax-credit-could-impact-teslas-deliveries-despite-ceo-elon-musk-claiming-otherwise" target="_blank" rel="noopener">경고했다</a>. First Trust Nasdaq Transportation ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>) 같이 광범위한 자동차 시장을 추적하는 ETF는 포트폴리오 내 기존 자동차 주식과 전기차 주식의 균형에 따라 성과가 엇갈릴 수 있다.
그러나 단기 변동성에도 불구하고 전기차 중심 ETF의 장기 전망은 글로벌 탈탄소화 추세와 밀접한 관련이 있다. 또한, 연방정부의 정책 철회는 특히 캘리포니아 및 기타 친전기차 주에서 주 차원의 이니셔티브로 상쇄될 가능성도 있다.
이 기사도 읽어보세요: <a style="font-size: revert; font-weight: revert;" href="https://kr.benzinga.com/news/usa/stocks/%EB%B1%85%ED%81%AC%EC%98%A4%EB%B8%8C%EC%95%84%EB%A9%94%EB%A6%AC%EC%B9%B4-%EB%93%B1-%EC%9B%94%EA%B0%80-%EB%8C%80%ED%98%95-%EC%9D%80%ED%96%89-%EC%B5%9C%EA%B3%A0%EC%9D%98-%EB%B6%84%EA%B8%B0/" target="_blank" rel="noopener">뱅크오브아메리카 등 월가 대형 은행 &#8216;최고의 분기&#8217;, 선거 변동성 속 거래 수익 245억 달러</a>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 미국 전기차(EV) 시장 점유율이 <a href="https://www.benzinga.com/news/24/07/39685198/severely-damaged-tesla-cybertruck-involved-in-collision-turns-up-for-auction">처음으로 절반 아래로</a> 떨어졌다.
어떤 일이 (What Happened): 일론 머스크(Elon Musk)가 이끄는 이 회사는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39502910/elon-musk-could-sell-at-least-100-000-new-lower-cost-models-next-year-tesla-has-ove" target="_blank" rel="noopener" data-google-interstitial="false">한 때 지배했던 부문</a>에서 더 많은 자동차 경쟁사들이 시장 점유율을 차지하는 것을 보고 있다.
화요일 리서치 회사인 콕스 오토모티브(Cox Automotive)가 발표한 새로운 추정에 따르면 테슬라의 미국 EV 시장 점유율은 2분기에 49.7%로 하락해 분기 중 처음으로 50% 아래로 떨어졌다. 이는 2023년 2분기에 게시된 시장 점유율 59.3%보다 감소한 수치이다.
콕스는 7월 11일 전체 2분기 EV 판매 보고서를 발표할 계획이지만, 가장 최근 뉴스레터에서 테슬라의 감소하는 시장 점유율을 포함한 일부 데이터를 살짝 엿볼 수 있었다. 이 숫자에 대한 분석은 다음과 같다:
<ul>
<li>테슬라의 미국 내 매출은 3개월 동안 6.3% 감소했다.</li>
<li>제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), 포드 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), 현대차 및 기아차의 EV 판매 호조로 인해 미국 내 2분기 총 판매량이 기록적인 330,463대 판매로 늘어났다.</li>
<li>이 총량은 분기별 판매량이 전년 동기 대비 11.3% 증가했으며, 2023년 4분기 동안 미국에서 판매된 EV 317,168대의 종전 기록을 넘어섰다.</li>
<li>2분기 미국 전체 자동차 판매에서 전기차 판매가 차지하는 비중은 8%로, 전 분기 7.1%, 전년 동기 7.2%보다 증가했다.</li>
<li>메르세데스-벤츠 등 유럽 고급차 제조사들의 판매량 감소로 전체 판매량이 감소했다.</li>
</ul>
또한 읽어볼 것: <a href="https://www.benzinga.com/news/24/07/39697397/zapp-electric-vehicles-shares-are-off-the-roof-what-you-need-to-know">잽 일렉트릭 비이클스 주식 매수 공세: 투자 팁</a>
콕스의 인더스트리 인사이트(Industry Insights) 이사인 스테파니 발데즈 스트리티(Stephanie Valdez Streaty)는 성명에서 &#8220;테슬라의 판매가 계속 감소하고 있으며 EV 판매 점유율이 처음으로 50% 미만인 반면 전반적인 전기 자동차 경쟁 환경은 더욱 강화되고 있다&#8221;고 말했다.
"이로 인해 가격 압박이 계속되고 있으며, 이는 EV 채택률을 서서히 높이는 데 도움이 된다. 적절한 제품을 적절한 가격으로 제공하고 탁월한 소비자 경험을 제공하는 자동차 제조업체가 채택을 주도할 것이다.&#8221;
뉴욕 타임스(New York Times)는 현재 많은 소비자가 유지 관리 및 수리를 제공할 수 있는 대규모 딜러 네트워크를 보유하고 있는 BMW나 포드와 같은 기존 자동차 제조업체로부터 전기 자동차를 구입하고 있다고 <a href="https://www.nytimes.com/2024/07/09/business/tesla-electric-vehicles-market-share.html#:~:text=Tesla%20accounted%20for%2049.7%20percent%20of%20electric%20vehicles,and%20Kia%2C%20the%20research%20firm%2C%20Cox%20Automotive%20said.">보도</a>했다.
주가 움직임: 이날 테슬라는 262.33달러에 3.71% 상승한 262.33달러에, 제너럴 모터스는 0.62% 하락한 46.26달러에서, 포드는 0.62% 떨어진 12.90달러에서 마감했다.
iShares Self-Driving EV and Tech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>)가 0.17% 하락하고 SPDR S&amp;P Kensho Smart Mobility ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>)가 0.06% 상승하면서 Global X Autonomous &amp; Electric Vehicles ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>)는 화요일에 0.45% 하락했다.
Image: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

iShares Self-Driving EV and Tech ETF

뉴스

에 대한 최신 뉴스 iShares Self-Driving EV and Tech ETF (ARCA:IDRV)

토요일, 2월 01, 2025

수요일, 1월 22, 2025

수요일, 7월 10, 2024

뉴스

파트너 / 기고자

벤징가 글로벌